TANGO THERAPEUTICS INC
NASDAQ: TNGX (Tango Therapeutics, Inc.)
Kemas kini terakhir: 4 jam lalu24.16
0.81 (3.47%)
| Penutupan Terdahulu | 23.35 |
| Jumlah Dagangan | 456,897 |
| Harga / Jualan (P/S) | 58.71 |
| Harga / Buku (P/B) | 3.84 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -788.76% |
| EPS Cair (TTM) | -1.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.16% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -135.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.25 M |
| Pulangan Atas Aset (ROA TTM) | -26.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tango Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 12.59% |
| % Dimiliki oleh Institusi | 97.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2026 | 13,900,620 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 9,081,201 |
| Trv Gp Iv, Llc | 30 Jun 2026 | 6,374,574 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 6,357,523 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| NEWCOMB JESSICA | - | 22.33 | -8,200 | -183,106 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,200 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -183,106 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 22.33 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| NEWCOMB JESSICA | Pegawai | 22 Sep 2026 | Jual automatik (-) | 8,200 | 22.33 | 183,106 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |